Literature DB >> 33666785

Identify potential miRNA-mRNA regulatory networks contributing to high-risk neuroblastoma.

Feng-Ling Shao1, Qing-Qing Liu1, Shan Wang2.   

Abstract

Neuroblastoma (NB) is a common tumor in children, usually in the retroperitoneum. After various treatments, low- and intermediate-risk patients have achieved good results, but the prognosis of high-risk patients is still very poor. Therefore, it is necessary to find new effective targets for the treatment of high-risk patients. In this study, comprehensive bioinformatics analysis was used to identify the differentially expressed genes (DEG and DEM) between high-risk patients and non-high-risk patients, and it was identified that ADRB2 may affect the survival status of high-risk patients due to miR -30a-5p regulation. The GSE49710, GSE73517, and GSE121513 datasets were downloaded from the Gene Expression Synthesis (GEO) database, and DEG and DEM were selected. Then, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were applied to the selected DEGs. The STRING database and Cytoscape software were used to construct protein-protein interaction (PPI) networks and perform modular analysis of the DEGs. The TARGET data set containing information on overall survival days were used for the prognostic analysis of central genes. We identified a total of 255 DEGs from GSE49710 and GSE73517, and 193 DEMs from GSE121513. We identified the 5 most important central genes from the PPI network, performed a prognostic analysis in the target data set, and verified their expression using RT-qPCR to select the most important ADRB2 gene to predict miRNA. Integrating the differential miRNA predicted by miRDB and miRSystem and GSE121513 between the targeted miRNA and the prognosis, miR-30a-5p was finally identified as the targeted miRNA of ADRB2.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Bioinformatics analysis; Biomarkers; Neuroblastoma; Prognostic; miRNA

Mesh:

Substances:

Year:  2021        PMID: 33666785     DOI: 10.1007/s10637-021-01064-y

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  53 in total

1.  Outcome after reduced chemotherapy for intermediate-risk neuroblastoma.

Authors:  David L Baker; Mary L Schmidt; Susan L Cohn; John M Maris; Wendy B London; Allen Buxton; Daniel Stram; Robert P Castleberry; Hiroyuki Shimada; Anthony Sandler; Robert C Shamberger; A Thomas Look; C Patrick Reynolds; Robert C Seeger; Katherine K Matthay
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

2.  Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN Study.

Authors:  Keith Holmes; Ulrike Pötschger; Andrew D J Pearson; Sabine Sarnacki; Giovanni Cecchetto; Javier Gomez-Chacon; Roly Squire; Enrique Freud; Adam Bysiek; Lucas E Matthyssens; Martin Metzelder; Tom Monclair; Jakob Stenman; Michal Rygl; Lars Rasmussen; Jean-Marc Joseph; Sabine Irtan; Stefano Avanzini; Jan Godzinski; Kristin Björnland; Martin Elliott; Roberto Luksch; Victoria Castel; Shifra Ash; Walentyna Balwierz; Geneviève Laureys; Ellen Ruud; Vassilios Papadakis; Josef Malis; Cormac Owens; Henrik Schroeder; Maja Beck-Popovic; Toby Trahair; Ana Forjaz de Lacerda; Peter F Ambros; Mark N Gaze; Kieran McHugh; Dominique Valteau-Couanet; Ruth Lydia Ladenstein
Journal:  J Clin Oncol       Date:  2020-07-08       Impact factor: 44.544

3.  Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.

Authors:  Douglas R Strother; Wendy B London; Mary Lou Schmidt; Garrett M Brodeur; Hiroyuki Shimada; Paul Thorner; Margaret H Collins; Edward Tagge; Stanton Adkins; C Patrick Reynolds; Kevin Murray; Robert S Lavey; Katherine K Matthay; Robert Castleberry; John M Maris; Susan L Cohn
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

4.  Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study.

Authors:  Katherine K Matthay; C Patrick Reynolds; Robert C Seeger; Hiroyuki Shimada; E Stanton Adkins; Daphne Haas-Kogan; Robert B Gerbing; Wendy B London; Judith G Villablanca
Journal:  J Clin Oncol       Date:  2009-01-26       Impact factor: 44.544

5.  Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.

Authors:  Balakrishna Koneru; Gonzalo Lopez; Ahsan Farooqi; Karina L Conkrite; Thinh H Nguyen; Shawn J Macha; Apexa Modi; Jo Lynne Rokita; Eduardo Urias; Ashly Hindle; Heather Davidson; Kristyn Mccoy; Jonas Nance; Vanda Yazdani; Meredith S Irwin; Shengping Yang; David A Wheeler; John M Maris; Sharon J Diskin; C Patrick Reynolds
Journal:  Cancer Res       Date:  2020-04-14       Impact factor: 12.701

Review 6.  Advances in Risk Classification and Treatment Strategies for Neuroblastoma.

Authors:  Navin R Pinto; Mark A Applebaum; Samuel L Volchenboum; Katherine K Matthay; Wendy B London; Peter F Ambros; Akira Nakagawara; Frank Berthold; Gudrun Schleiermacher; Julie R Park; Dominique Valteau-Couanet; Andrew D J Pearson; Susan L Cohn
Journal:  J Clin Oncol       Date:  2015-08-24       Impact factor: 44.544

Review 7.  Neuroblastoma.

Authors:  John M Maris; Michael D Hogarty; Rochelle Bagatell; Susan L Cohn
Journal:  Lancet       Date:  2007-06-23       Impact factor: 79.321

8.  High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial.

Authors:  Andrew D J Pearson; C Ross Pinkerton; Ian J Lewis; John Imeson; Caroline Ellershaw; David Machin
Journal:  Lancet Oncol       Date:  2008-03       Impact factor: 41.316

Review 9.  Neuroblastoma Origin and Therapeutic Targets for Immunotherapy.

Authors:  Irina V Kholodenko; Daniel V Kalinovsky; Igor I Doronin; Sergey M Deyev; Roman V Kholodenko
Journal:  J Immunol Res       Date:  2018-07-11       Impact factor: 4.818

10.  Exosomes from N-Myc amplified neuroblastoma cells induce migration and confer chemoresistance to non-N-Myc amplified cells: implications of intra-tumour heterogeneity.

Authors:  Pamali Fonseka; Michael Liem; Cemil Ozcitti; Christopher G Adda; Ching-Seng Ang; Suresh Mathivanan
Journal:  J Extracell Vesicles       Date:  2019-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.